학술논문

LNK (SH2B3): paradoxical effects in ovarian cancer
Document Type
article
Source
Oncogene. 34(11)
Subject
Biochemistry and Cell Biology
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Biological Sciences
Rare Diseases
Cancer
Ovarian Cancer
2.1 Biological and endogenous factors
Aetiology
14-3-3 Proteins
Adaptor Proteins
Signal Transducing
Animals
Cell Adhesion
Cell Line
Tumor
Cell Movement
Cell Proliferation
Cell Size
Female
Humans
Intracellular Signaling Peptides and Proteins
Mice
Mice
Inbred NOD
Mice
SCID
Mitogen-Activated Protein Kinases
Neoplasm Transplantation
Ovarian Neoplasms
Protein Binding
Proteins
Proto-Oncogene Proteins c-akt
Signal Transduction
Transplantation
Heterologous
Clinical Sciences
Oncology & Carcinogenesis
Biochemistry and cell biology
Oncology and carcinogenesis
Language
Abstract
LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic cells. In these cells, it downregulates activated tyrosine kinases at the cell surface resulting in an antiproliferative effect. To date, no studies have examined activities of LNK in solid tumors. In this study, we found by in silico analysis and staining tissue arrays that the levels of LNK expression were elevated in high-grade ovarian cancer. To test the functional importance of this observation, LNK was either overexpressed or silenced in several ovarian cancer cell lines. Remarkably, overexpression of LNK rendered the cells resistant to death induced by either serum starvation or nutrient deprivation, and generated larger tumors using a murine xenograft model. In contrast, silencing of LNK decreased ovarian cancer cell growth in vitro and in vivo. Western blot studies indicated that overexpression of LNK upregulated and extended the transduction of the mitogenic signal, whereas silencing of LNK produced the opposite effects. Furthermore, forced expression of LNK reduced cell size, inhibited cell migration and markedly enhanced cell adhesion. Liquid chromatography-mass spectroscopy identified 14-3-3 as one of the LNK-binding partners. Our results suggest that in contrast to the findings in hematologic malignancies, the adaptor protein LNK acts as a positive signal transduction modulator in ovarian cancers.